Skip to main content

Table 5 Risk group distribution before and after mpMRI of the prostate

From: Guidance of treatment decisions in risk-adapted primary radiotherapy for prostate cancer using multiparametric magnetic resonance imaging: a single center experience

  Clinical staging Relative upward shift by mpMRI Relative downward shift by mpMRI mpMRI staging
Low-risk group 14 (11.5%) 57.1% n.a. 7 (5.7%)
Intermediate-risk group 52 (42.6%) 30.8% 0% 44 (36.1%)
High-risk group 53 (43.4%) 13.2% 5.7% 59 (48.4%)
Nodal metastases (cN1) 3 (2.5%) 0% 33.3% 9 (7.4%)
Distant metastases (cM1) 0 n.a. n.a. 3 (2.5%)
  1. Risk groups for patients (n = 122) were defined according to the National Comprehensive Cancer Network prostate cancer guidelines based on T stage, serum PSA level and the Gleason score derived from prostate biopsy. n.a. = not available.
\